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An overview of the National Typhoid and Paratyphoid Fever Surveillance (NTPFS) system is available at  
http://www.cdc.gov/ncezid/dfwed/PDFs/typhi_surveillance_overview_508c.pdf. 
National Typhoid and Paratyphoid Fever Surveillance Data 
States reporting at least one typhoid or paratyphoid fever1 case to the NTPFS during 2011 are shown in Figures 1 and 2.
•	 37 states reported  347 typhoid fever cases (Figure 1)
•	 21 states reported  107 paratyphoid fever cases (106 Paratyphi A; 1 Paratyphi C) (Figure 2)
Figure 1.  States reporting at least one typhoid fever case to National Typhoid and Paratyphoid 







































1 Paratyphoid fever is caused by Salmonella serotypes Paratyphi A, Paratyphi B, and Paratyphi C. Two distinct pathotypes of Paratyphi B are recognized; 
one is associated with paratyphoid fever and the other is associated with uncomplicated gastroenteritis. The two pathotypes have distinct virulence 
characteristics, and are differentiated based on the ability to ferment tartrate. The paratyphoidal pathotype is unable to ferment tartrate and is designated 
serotype Paratyphi B; the nonparatyphoidal pathotype ferments tartrate and is designated serotype Paratyphi B var. L(+) tartrate+. Only those isolates 
laboratory confirmed as not able to ferment tartrate are included in the annual NTPFS summary.  For many Paratyphi B reports submitted to CDC, this 
information is not available; these reports are therefore excluded from the NTPFS summary.
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Figure 2. States reporting at least one paratyphoid fever case to National Typhoid and Paratyphoid Fever 






















Demographic and clinical characteristics of patients with typhoid fever and paratyphoid fever are shown in Tables 1 and 2.
•	 The median age of patients with typhoid fever was 24 years
•	 The median age of patients with paratyphoid fever was  26 years 
•	 One patient with typhoid fever died (0.3%)
•	 One patient with paratyphoid fever died (0.3%)
Table 1. Demographic and clinical characteristics of patients with typhoid fever reported to  
National Typhoid and Paratyphoid Fever Surveillance, 2011 (n=347).
Characteristic (total number) Count Percent
Median age in years (range) 24 (<1–89) --
Female (n=344) 152 44
US Citizen (n=284) 124 44
Vaccinated* (n=280) 9 3
ViCPS 3 33
Ty21a 1 11
Site of isolation (n=316)
Blood 273 87
Stool 34 11
Gall bladder 9 3
Other  -- --
Hospitalized (n=337)  260 77
Died (n=329) 1 0.3
* Received typhoid vaccination within 5 years before onset of illness 
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Table 2. Demographic and clinical characteristics of patients with paratyphoid fever reported to 
National Typhoid and Paratyphoid Fever Surveillance, 2011 (n=107). 
Characteristic (total number) Count Percent
Median age in years (range) 26 (1–83) --
Female (n=107) 49 46
US Citizen (n=96) 44 46
Vaccinated* (n=79) 3 4
ViCPS 1 33
Ty21a -- --
Site of isolation (n=101)
Blood 93 92
Stool 8 8
Gall bladder -- --
Other  -- --
Hospitalized (n=107)  75 70
Died (n=104) 1 1
* Received typhoid vaccination within 5 years before onset of illness.  
(Note that typhoid vaccination does not protect against paratyphoid fever.) 
Travel destinations are shown in Table 3.
•	 303 (88%) patients with typhoid fever and 93 (86%) patients with paratyphoid fever reported traveling or living outside 
the United States in the 30 days before illness onset
•	 Visiting friends or relatives was the most common reason for travel for patients with typhoid fever (70%) and 
paratyphoid fever (69%)
Table 3.  Travel destinations reported to National Typhoid and Paratyphoid Fever Surveillance, 2011. 
Travel Destination Typhoid (n=303) Paratyphoid (n=93)
no. (%) no. (%)
India 208 (69) 71 (76)
Bangladesh 25 (8) 8 (9)
Pakistan 23 (8) 10 (11)
Mexico 10 (3) --
Nepal  5 (2) --
Other 29 (10) 4 (5)
Unknown 3 (0.01) --
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Surveillance performance measures
Reporting statistics and goals for National Typhoid and Paratyphoid Fever Surveillance (below) were proposed at the 2012 
Council of State and Territorial Epidemiologists (CSTE) Annual Meeting (2).  
State-specific summaries were sent to state epidemiologists in January 2013.  Health department personnel may request 
their state’s reporting statistics by emailing edebresponse@cdc.gov. 
Table 4.  National typhoid fever reporting statistics by year, National Typhoid and Paratyphoid Fever Surveillance (NTPFS), 
2000–2011.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Number of jurisdictions reporting 
typhoid fever cases to NTPFS1
50 50 50 50 50 50 50 50 50 50 50 49
Number of case reports received 258 231 202 279 248 207 327 413 439 346 432 348
NTPFS cases as a percentage of  
NNDSS reports2
63% 55% 53% 77% 73% 57% 90% 94% 95% 91% 112%3 88%
Reporting timeliness 
Median days from specimen isolation 
date to date report form completed 
20 27 15 15 11 14 33 32 22 18 32 24
Reporting completeness 
Proportion of reports with “complete” 
demographic information5
93% 97% 95% 95% 92% 94% 93% 96% 87% 78% 88% 94%
Proportion of reports with “complete” 
epidemiologic information6
95% 94% 95% 95% 88% 92% 73% 74% 82% 77% 86% 71%
Proportion of reports with “complete” 
travel destination information7
98% 97% 99% 99% 98% 98% 98% 99% 98% 99% 99% 99%
Proportion of reports with “complete” 
vaccination information8
96% 98% 99% 97% 97% 99% 99% 96% 96% 95% 97% 80%
Proportion of reports with “complete” 
vaccine type information9
20% 10% 75% 33% 36% 50% 57% 44% 24% 57% 46% 44%
Table 5.  National paratyphoid fever reporting statistics by year, National Typhoid and Paratyphoid Fever Surveillance 
(NTPFS), 2007–2011.
 2007 2008 2009 2010 2011
Number of jurisdictions reporting paratyphoid fever cases to NTPFS1 50 50 50 50 49
Number of case reports received2 4 85 78 115 107
Reporting timeliness
Median days from specimen isolation date to date report form completed 69 20 76 67 35
Reporting completeness
Proportion of reports with “complete” demographic information5 100% 88% 77% 94% 96%
Proportion of reports with “complete” epidemiologic information6                   100% 91% 90% 90% 80%
Proportion of reports with “complete” travel destination information7 100% 99% 100% 100% 100%
Proportion of reports with “complete” vaccination information8 100% 90% 94% 97% 74%
Proportion of reports with “complete” vaccine type information9 100% 60% 83% 69% 100%
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1 Includes District of Columbia and Guam 
2 Two jurisdictions do not report to NNDSS, these cases were excluded in the comparison 
3 Is not calculable where no cases are reported to NNDSS; can be greater than 100% if more cases are reported to NTPFS than to NNDSS
4 Is not calculable where no NTPFS reports are received or where specimen isolation date or date of form completion is not completed
5 For purposes of this report, “complete” demographic information is defined as information for all of the following: Age or Date of birth, Sex, and 
Hospitalization status 
6 For purposes of this report, “complete” epidemiologic information is defined as information for all of the following: Travel, Receiving vaccine within 5 years 
before illness onset, Whether the patient was a food handler, Outbreak status, and Citizenship
7 For purposes of this report, “complete” travel destination information is defined as report of at least one travel destination if patient reported travel 
outside of the US  in the 30 days before illness onset 
8 For purposes of this report, “complete” vaccination information is defined as a response of “Yes”, “No” or “Don’t know” regarding receipt of typhoid 
vaccination primary series or booster within 5 years before onset of illness      
9 For the purposes of this report, “complete” vaccine type information was calculated for patients whose reports specified receipt of typhoid fever 
vaccination within 5 years before illness onset; a response of “unknown” was considered missing for this variable 
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NNDSS Data
The National Notifiable Disease Surveillance System (NNDSS) collects and compiles reports of nationally notifiable infectious 
diseases, including typhoid fever. Paratyphoid fever is not nationally notifiable. Reports can be found at  
http://www.cdc.gov/mmwr/mmwr_nd/index.html 
Antimicrobial Resistance Data
The National Antimicrobial Resistance Monitoring System (NARMS) monitors antimicrobial resistance among enteric bacteria 
(including Salmonella serotype Typhi) from humans.  In Enterobacteriaceae, resistance to nalidixic acid, an elementary 
quinolone, correlates with decreased susceptibility to ciprofloxacin (MIC ≥0.12 μg/mL) and possible fluoroquinolone 
treatment failure. For Salmonella serotypes Typhi and Paratyphi, resistance to traditional first-line antimicrobial agents, 
ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (ACT/S), is an important multidrug resistance pattern.
The most recently published NARMS annual report is from 2010, available at  
http://www.cdc.gov/narms/pdf/2010-annual-report-narms.pdf (1).  The 2010 data showed the following:   
For Salmonella serotype Typhi isolates
•	 69% were resistant to nalidixic acid
•	 3% were resistant to ciprofloxacin
•	 No isolates were resistant to ceftriaxone
•	 11% were multidrug  resistant
For Salmonella serotype Paratyphi isolates
•	 90% were resistance to nalidixic acid
•	 0% were resistant to ciprofloxacin
•	 No isolates were resistant to ceftriaxone
•	 1% were multidrug  resistant 
Outbreak Data
The Foodborne Disease Outbreak Surveillance System (FDOSS) collects reports of foodborne disease outbreaks from local, 
state, tribal, and territorial public health agencies. Reports can be found at  
http://cdc.gov/outbreaknet/surveillance_data.html. 
•	 In 2011, no typhoid fever outbreaks were reported. 
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